[1] Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepatiti, 2004, 11 (2), 97.
[2] http://www.who.int/mediacentre/factsheets/fs204/en/.
[3] Dienstag JL. Hepatitis B Virus Infection[J]. New Eng J Med, 2008, 359 (14), 1486.
[4] Lui YYN,Chan HLY. Treatment of chronic hepatitis B:focus on telbivudine[J]. Expert Rev Anti Infect Ther, 2009, 7 (3), 259.
[5] Cheng PN,Chang TT. Entecavir:a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients[J]. Expert Rev Anti Infect Ther, 2008, 6 (5), 569.
[6] Lv Z,Sheng C,Wang T,et al. Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives[J]. J Med Chem, 2009, 53, 660.
[7] Dong H,Li K,Zheng C,et al. Synthesis and antitumor activity of novel 3-(substituted amino)-chromone derivatives[J]. Acta Chim Sin, 2009, 67(8), 819.